Lexology October 31, 2024
DLA Piper

In this two-part article, we delve into the complexities of gene editing in plants and the ongoing EU legislative debates, followed by an exploration of gene drives and their regulatory challenges. Part 1 examines the legal status of gene-edited plants under EU law and the European Commission’s recent proposal for a new regulation, while Part 2 focuses on the broader implications of gene drives, highlighting both national and international legislative frameworks and future regulatory considerations.

Part 1: Gene editing use in plants

Some 9,000 to 11,000 years ago, humans began to cultivate plants, selecting those with desirable characteristics and using their seeds for future harvests. Today, so called New Genomic Techniques (NGTs), a term used to describe innovative gene editing...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: Biotechnology, Pharma / Biotech
Bristol Myers Squibb says Alzheimer's is the biggest market for new schizophrenia drug
At JPM, Eli Lilly’s CEO Explains Why Mounjaro, Zepbound Sales Were Lower Than Expected
NIH's unfinished business
Lilly blames slower-than-expected growth for 2024 sales miss
AbbVie to write off $3.5B over failed schizophrenia drug

Share This Article